Actinium Pharmaceuticals, Inc.
ATNM · XNYSCIK 1388320fmd_18663XMBB5PNAD5PRP2E594NB1Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2001 to Jun 30, 2026, 73 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 1 | 1 | 0 | – | 0 |
| Cost of revenue | – | – | – | – | – | 1 | – | – | – | – |
| Net interest income | (0) | 0 | 0 | 0 | 0 | 0 | 1 | 3 | – | – |
| Gross profit | – | – | – | – | – | 0 | – | – | – | – |
| Research and development | 18 | 18 | 17 | 17 | 16 | 18 | 23 | 39 | 30 | 21 |
| Total operating expenses | 27 | 27 | 24 | 22 | 22 | 26 | 35 | 52 | 42 | 36 |
| Operating income | (27) | (27) | (24) | (22) | (22) | (25) | (34) | (52) | (42) | (36) |
| Interest expense | 0 | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | 3 | 4 | 2 |
| Other non-operating income (expense) | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 2 |
| Income before taxes | – | – | – | – | – | – | – | – | – | (34) |
| Income tax expense | – | – | – | – | – | – | – | – | – | – |
| Net income | (24) | (27) | (24) | (22) | (22) | (25) | (33) | (49) | (38) | (34) |
| Net income to common shareholders | – | – | (24) | (22) | (22) | (25) | – | – | – | – |